Author, date and country | Patient group | Study type (level of evidence) | Outcomes | Key results | Study Weaknesses |
---|---|---|---|---|---|
Haude M, Steffen W, Erbel R, Meyer J 1990 Germany | 24 patients with severe left heart failure (NYHA Classification Class III or IV) in the intensive care setting. | Randomized crossover study. Patients all monitored using a pulmonary artery thermodilution catheter. Randomized to receive either 25mg captopril or 0.8mg nitroglycerin sublingually then monitored for 3h. After parameters had returned to base-line levels the patients received the other treatment arm and were again monitored for 3h. | Pre- and after-load parameters | Nitroglycerin and captopril improved parameters to significantly (P<0.001 for each) | Not clear how patients were recruited for this study. Method of randomisation not explained. No blinding. No sample size estimate. No mention of ethical approval. Clinical outcomes only mentioned briefly - 22/24 patients reported improvement, 5/24 patients reported headache with nitroglycerin, no other side effects. |
Increase in cardiac index | Captopril increased this significantly more than nitroglycerin (+49.2% vs. +25% P<0.001) | ||||
Peak onset | Captopril 47-84 minutes vs. nitroglycerin at 25-55 minutes (P<0.001) | ||||
Duration of action | Captopril 117-162 minutes vs nitroglycerin at 68-120 minutes (P<0.001) | ||||
Adigun AQ et al 1998 Nigeria | 17 patients presenting to an Emergency Department with severe, acute left ventricular failure. | Prospective, randomised trial. Randomised to receive either 50mg captopril and 1mg prazosin orally or 30mg hydralazine intravenously and 30mg isosorbide dintrate orally. Patients required to be hypertensive with pulmonary oedema on the chest x-ray and a dilated heart. | Systolic and diastolic blood pressure | Significant drop in both values in each group. (P<0.001). No significant difference between treatments. | Study carried out in Nigeria where LVF is often secondary to malignant hypertension rather than to coronary artery disease. Recruitment not clearly described, only 17 patients recruited in 2y. No power calculation. Clinical outcome described only briefly: 4 patients from captopril group and 4 patients from hydralazine group required dialysis for renal failure. One of the patients from the hydralazine group died before his dialysis could be commenced. No other patients died. |
Respiratory rate | Both treatments produced significant drop in respiratory rate (P=0.001). Captopril/prazosin group had significantly greater drop in respiratory rate (P=0.034). |